Company: BGLC
Filing Date: 2025-08-18
Form Type: 10-Q
Source: 0001477932-25-006023
Chunk: 28

Company: BioNexus Gene Lab Corp
Filing Date: 2025-08-18
Form: 10-Q
Item: Part I, Item 1
Chunk 28
---
,985   12.44%  10.56% $171,291  $112,482 Vendor C $-  $274,081   -   16.26% $-  $274,842 Vendor D $-  $181,885   -   10.79% $-  $117,148   $875,347  $913,214   46.26%  54.18% $819,181  $809,033   a) Major customers For six months ended June 30, 2025, and 2024, respectively, the Company did not have any material recognizable major customers accounted for 10% or more of the Company’s revenue b) Major suppliers For six months ended June 30, 2025, and 2024, respectively, the suppliers who accounted for 10% or more of the Company’s cost of sales and their balances at period ended are presented as follows:    2025  2024  2025  2024  2025  2024   Purchase  Percentage of purchases  Accounts payable trade Vendor A $1,081,275  $671,441   29.34%  18.13% $647,890  $304,561 Vendor B $561,103  $492,944   15.22%  13.31% $171,291  $112,482 Vendor C $-  $620,397   -   16.76% $-  $274,842   $1,642,378  $1,784,782   44.56%  48.20% $819,181  $691,885 

 22Table of Contents

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND 2024 

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

NOTE 12 – STOCKHOLDERS’ EQUITY As at June 30, 2025 and December 31, 2024, the Company